2ϩ is of primary importance in the pathogenesis of ischemia and reperfusion injury in the myocardium. Recent studies have suggested that a massive Ca 2ϩ influx may occur as a consequence of Na ϩ -Ca 2ϩ exchange via the sodium-calcium exchanger (NCX) during reperfusion which, in turn, may be caused by an accumulation of Na ϩ via the sodium-hydrogen exchanger (NHE) during ischemia.
Intracellular Ca
2ϩ is of primary importance in the pathogenesis of ischemia and reperfusion injury in the myocardium. Recent studies have suggested that a massive Ca 2ϩ influx may occur as a consequence of Na ϩ -Ca 2ϩ exchange via the sodium-calcium exchanger (NCX) during reperfusion which, in turn, may be caused by an accumulation of Na ϩ via the sodium-hydrogen exchanger (NHE) during ischemia. 1, 2) This results in an intracellular Ca 2ϩ overload, the detrimental effects of which include myocardial contracture, stunning, necrosis, and reperfusion arrhythmia. [3] [4] [5] [6] [7] [8] [9] NCX functions in both reverse and forward modes, and it is well known that an overactive reverse NCX causes Ca 2ϩ overload. Inhibition of reverse NCX overactivity would effectively block this overload and prevent damage to the myocardium in ischemiareperfusion. Therefore, reverse NCX inhibitors are currently considered to be beneficial in treating disease states. 10, 11) Recently, quinazoline derivatives 12) and a series of benzyloxyphenyl derivatives [13] [14] [15] [16] have been identified as NCX inhibitors. KB-R7943 (1) is one of the most widely known NCX inhibitors, and is used as a tool in heart and renal failure models, 17, 18) and SEA0400 (2) is well known as a potent reverse NCX inhibitor that is efficacious in myocardial ischemia-reperfusion injury [19] [20] [21] [22] (Fig. 1) . We have recently discovered reverse NCX inhibitors, such as 3, which we have reported elesewhere. 16, 23, 24) To create potent and selective reverse NCX inhibitors, we have now designed a novel class of NCX inhibitors based on 3, and in this paper describe the results of our work on the synthesis and structure-activity relationships (SAR) of this novel class of benzyloxyphenyl derivatives.
Chemistry
Compounds 4a-e were converted into compounds 5a-e via O-alkylation with 1-(bromomethyl)-3-fluorobenzene. Desired compounds 6a-e were prepared from 5a-e by condensation with pyridin-4-ylmethylamine as shown in Chart 1. Intermediate 4e was synthesized from 7 via S-alkylation with the corresponding alkylbromide. Compounds 9a-c were obtained by O-alkylation of 8 15) with the corresponding alkylbromides followed by hydrolysis of the ester group. Compounds 10a-c were afforded by condensation with 9a-c and pyridin-4-ylmethylamine. Compound 8 was converted into a compound whose amino group was protected with a phthaloyl group, followed by deprotection of the phthaloyl group with hydrazine to give compound 11. Compound 12 was afforded via condensation of 11 with pyridin-4-ylacetic acid. Compound 13 was prepared by O-alkylation of 8 with tert-butyl(2-bromoethyl)carbamate followed by deprotection of the tert-butoxycarbonyl group. Desired compound 14 was obtained from 8 via condensation with bis(trichloromethyl)carbonate and pyridin-4-ylmethylamine.
Results and Discussion
In order to measure the inhibitory effect of the synthesized compounds on the reverse mode of NCX activity, an Na ϩ -dependent Ca 2ϩ influx assay was performed according to reported protocols, using 45 Ca and CCL39 cells stably expressing NCX1.1. 13, 23) The inhibitory effect on the forward mode of NCX activity was assayed by a cell necrosis assay, which also used NCX1.1-expressing CCL39 cells. 23, 25) The inhibitory potencies of our novel compounds were thus evaluated in both reverse and forward NCX assays. These compounds were then compared to reference compounds KB-R7943 (1), SEA0400 (2) and compound 3.
The structure-activity relationships of our novel series of NCX inhibitors are summarized in Tables 1 and 2 . We have reported a SAR of the nicotinamide part. 16 3, with an N-(pyridin-4-ylmethyl)piperidine-1-carboxamide structure, had a potent inhibitory activity against reverse NCX with an IC 50 value of 0.22 mM. To create novel structures in the position of the piperidine-1-carboxamide moiety, we attempted to change the piperidine-1-carboxamide linker into an alkyl chain structure. To examine the effect of the length of the alkyl-linker on reverse NCX inhibitory activity, we evaluated compounds with several different lengths of structure between the phenoxy and pyridine parts (Table 1) . Compounds 6a and 6b, with a linker length of 5 atoms between the phenoxy part and the pyridine ring produced an extreme reduction in reverse NCX inhibitory activity compared to compound 3. A compound with a 6-atoms linker (6c) had similar inhibitory activity as 3. When we changed the linker length to 7 atoms (10a), the inhibitory activity was increased. This prompted us to introduce longer linkages, with 8 atoms (10b) and 9 atoms (10c) between the phenoxy part and the pyridine ring. However, the inhibitory activities of 10b and 10c were reduced with increasing linker length. Compound 10a showed the most potent inhibitory activity, with an IC 50 value of 0.10 mM against reverse NCX ( Table 1 ). The results indicated that linker length is important for inhibitory activity against reverse NCX, and also prompted us to introduce another linker connecting the phenoxy part with the pyridine ring as shown in Table 2 . Replacements of -O-(10a) with -C-(6d) and -S-(6e) slightly reduced inhibitory activity against reverse NCX. Compound 12, with an inverse amide to compound 10a, also showed slightly increased inhibitory activity over 10a with an IC 50 value of 0.085 mM against reverse NCX. Compound 12 was 3-fold more potent than SEA0400 (2), and also showed higher selectivity. Replacement of the amide linkage with a urea linkage (14) resulted in a 2.6-fold decrease in inhibitory potency against reverse NCX compared to 10a. Each of these derivatives with an alkyl chain linker showed higher selectivity than 3.
Conclusion
A series of benzyloxyphenyl derivatives have been prepared and evaluated for their inhibitory activities against the reverse and forward modes of NCX. By modifying the piperidine-1-carboxamide moiety, we found that a compound containing a N-propyl-2-pyridin-4-ylacetamide (12) , rather than a N-(pyridin-4-ylmethyl)piperidine-1-carboxamide (3), had enhanced reverse NCX inhibitory activity and increased selectivity. Compound 12 (YM-270951) had an IC 50 value of 0.085 mM against reverse NCX and higher selectivity. The reverse NCX inhibitory activity of 12 was approximately 3-times greater than that of of SEA0400 (2). This study could provide a novel approach to more potent reverse NCX inhibitors with higher selectivity.
Experimental
Chemistry Melting points were determined with a Yanaco MP-500D melting point apparatus or a Buchi B-545 melting point apparatus and are uncorrected.
1 H-NMR spectra were recorded on a JEOL JNM-LA300 or a JNM-EX400 spectrometer and the chemical shifts are expressed in d (ppm) values with tetramethylsilane as an internal standard (in NMR description, sϭsinglet, dϭdoublet, tϭtriplet, mϭmultiplet, and brϭbroad peak). Mass spectra were recorded on a Hitachi M-80 or a JEOL JMS-LX2000 spectrometer. The elemental analyses were performed with a Yanaco MT-5 microanalyzer (C, H, N) and were within Ϯ0.4% of theoretical values. Drying of organic solutions during workup was done over anhydrous Na 2 SO 4 .
Ethyl 4-[(4-Hydroxyphenyl)sulfanyl]butanoate (4e)
To a mixture of 4-sulfanylphenol (7) (1.26 g, 10.0 mmol) in MeCN (30 ml) were added K 2 CO 3 (2.07 g, 15 mmol) and ethyl 4-bromobutanoate (1.57 ml, 11.0 mmol) at room temperature. The mixture was stirred for 1 h and partitioned between CHCl 3 and H 2 O. The organic layer was dried and concentrated in vacuo. The residue was purified by column chromatography on silica gel (hexane : AcOEtϭ1 : 0-4 : 1) to give 4e as a colorless oil ( 
3-{4-[(3-Fluorobenzyl)oxy]phenyl}propanoic Acid (5b)
Compound 5b was prepared from 4b by a procedure similar to that described for 5a.
Compound 5b was obtained as a colorless solid (89% in 2 steps): 
4-{4-[(3-Fluorobenzyl)oxy]phenyl}butanoic Acid (5c)
Compound 5c was prepared from 4c by a procedure similar to that described for 5a. Compound 5c was obtained as a colorless solid (89% in 2 steps): 
5-{4-[(3-Fluorobenzyl)oxy]phenyl}pentanoic Acid (5d) Compound 5d
was prepared from 4d by a procedure similar to that described for 5a. Compound 5d was obtained as a colorless powder (94% in 2 steps): 
2-{4-[(3-Fluorobenzyl)oxy]phenoxy}-N-(pyridin-4-ylmethyl)acetamide
Hydrochloride (6a) To a mixture of pyridin-4-ylmethylamine (108 mg, 1.00 mmol), 1-hydroxybenzotriazole (HOBt) (68 mg, 0.50 mmol), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (WSC · HCl) (211 mg, 1.10 mmol) and THF (5 ml) was added 5a (276 mg, 1.00 mmol) at room temperature. The mixture was stirred for 2 h. The reaction mixture was quenched by saturated NaHCO 3 . The mixture was partitioned between CHCl 3 and aqueous NaOH. The organic layer was dried and concentrated in vacuo to give light yellow solid. The residue was purified by column chromatography on silica gel (CHCl 3 : MeOHϭ98 : 2) to afford a free base of 6a (256 mg). The compound was dissolved in AcOEt, CH 3 CN and MeOH, the mixture was treated with 4 M HCl/AcOEt (0.210 ml, 0.838 mmol) and was recrystallized to give 6a as a colorless solid (182 mg, 45%): mp 154-157°C; 
N-(4-{4-[(3-Fluorobenzyl)oxy]phenyl}butyl)-2-pyridin-4-ylacetamide Oxalate (6d)
To a mixture of pyridin-4-ylmethylamine (108 mg, 1.00 mmol), 1-hydroxybenzotriazole (HOBt) (68 mg, 0.50 mmol), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (WSC · HCl) (211 mg, 1.10 mmol) and THF (6 ml) was added 5d (302 mg, 1.00 mmol) at room temperature. The mixture was stirred for 3 h. The reaction mixture was quenched by saturated NaHCO 3 . The mixture was partitioned between CHCl 3 and aqueous NaOH. The organic layer was dried and concentrated in vacuo to give light yellow solid. The residue was purified by column chromatography on silica gel (CHCl 3 : MeOHϭ98 : 2-96 : 4) to afford a free base of 6d (371 mg). The compound was dissolved in MeOH. To the mixture was added oxalic acid (94 mg, 1.04 mmol). The mixture was concentrated in vacuo, the residue was recrystallized from AcOEt-CH 3 CN (5 : 1) to give 6d as a colorless powder (284 mg, 59%): mp 128-130°C; , DMSO-d 6 ) d 1.58-1.73 (4H, m), 2.23-2.30 (2H, m) 73 (2H, m), 2.18-2.26 (2H, m), 3.84-3.91 (2H, m) {4-[(3-Fluorobenzyl)oxy]phenoxy}-N-(pyridin-4-ylmethyl) butanamide Hydrochloride (10a) Compound 10a was prepared from 9a by a procedure similar to that described for 6a. Compound 10a was obtained as a colorless powder (77%): mp 144-146°C; 
4-

N-(2-{4-[(3-Fluorobenzyl)oxy]phenoxy}ethyl)-NЈ-(pyridin-4-ylmethyl)urea Hydrochloride (14)
To a mixture of bis(trichloromethyl)carbonate (190 mg, 0.64 mmol) in THF (5 ml) was added a mixture of 13 (430 mg, 1.60 mmol), Et 3 N (0.335 ml, 2.40 mmol) in THF (5 ml) at 0°C. The mixture was stirred at room temperature for 1 h. To the mixture was added a mixture of 4-aminomethylpyridine (208 mg, 1.92 mmol), Et 3 N (0.268 ml, 1.92 mmol) in THF (5 ml) at 6°C. The mixture was stirred at room temperature for 1 h. The reaction mixture was quenched by saturated NaHCO 3 . The mixture was partitioned between CHCl 3 and aqueous NaOH. The organic layer was dried and concentrated in vacuo to give light yellow solid. The residue was purified by column chromatography on silica gel (CHCl 3 : MeOHϭ92 : 8) to afford a free base of 14 (260 mg). The compound was dissolved in AcOEt (7 ml) and MeOH (5 ml), the mixture was treated with 4 M HCl/AcOEt (0.197 ml, 0.789 mmol) and concentrated in vacuo. The residue was recrystallized from AcOEt-CH 3 CN (5 : 2) to give 14 as a beige powder (231 mg, 33%): mp 115-116°C; Pharmacology The methods of 45 Ca influx assay and Cell necrosis assay were described in previous report. 23) 
